Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
NCT03518073 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zagotenemab
Study Locations (20)
California
- Pharmacology Research Institute — Encino
- Fullerton Neurology and Headache Center — Fullerton
- Irvine Clinical Research Center — Irvine
- Pharmacology Research Institute — Los Alamitos
- National Research Institute - Huntington Park — Panorama City
- Anderson Clinical Research — Redlands
- Pacific Research Network — San Diego
- Univ of California San Francisco — San Francisco
- Syrentis Clinical Research — Santa Ana
Florida
- JEM Research Institute — Atlantis
- Julie B. Schwartzbard, MD, PA — Aventura
- Quantum Laboratories Clinical Research — Deerfield Beach
- Brain Matters Research — Delray Beach
- Neuropsychiatric Research Center of Southwest Florida — Fort Myers
- Infinity Clinical Research, LLC — Hollywood
- VIN-Victor Faradji — Miami
- Renstar Medical Research — Ocala
Arizona
- Banner Alzheimer's Institute — Phoenix
- Center for Neurosciences — Tucson
Connecticut
- New England Institute for Clinical Research — Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2018-04-30 |
| Est. Completion | 2021-10-25 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03518073
The ClinicalTrials.gov registry entry for NCT03518073 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 704 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Alzheimer Disease (AD) appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03518073 reports 20 study locations spanning 4 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03518073 about?
NCT03518073 is a clinical study titled "A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease". The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
What is the current status of trial NCT03518073?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2018-04-30. Estimated completion is 2021-10-25.
What conditions does trial NCT03518073 study?
This clinical trial studies the following conditions: Alzheimer Disease (AD). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03518073?
The interventions under investigation include: Placebo (DRUG), Zagotenemab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03518073?
This trial is sponsored by Eli Lilly and Company, which has 704 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03518073 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.